Regeneron (REGN) and Sanofi (SNY) announced that the FDA has approved Dupixent for the treatment of adult patients with bullous pemphigoid. The FDA approval is based on data from the pivotal ADEPT Phase 2/3 trial that evaluated the efficacy and safety of Dupixent compared to placebo in adults with moderate-to-severe BP.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron Shareholders Approve Key Proposals at 2025 Meeting
- Regeneron’s Promising Blood Thinner Program: Analyst’s Buy Rating Highlights Market Potential
- Regeneron, Sanofi announce Dupixent outperformed Xolair
- 23andMe confirms sale of business to TTAM Research Institute for $305M
- Regeneron: Attractive Valuation and Strong Growth Prospects Justify Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue